---
provider: claude_code
model: claude-haiku-5-5, claude-sonnet-5-5
cached: false
start_time: '2026-10-24T15:33:17.630991'
end_time: '2026-10-24T15:34:26.569914'
duration_seconds: 68.94
template_file: templates/disease_pathophysiology_research.md
template_sha: "f452f0a9c7e3536175154b9683c45663f686f283"
template_variables:
  disease_name: Brain Malformations With Or Without Urinary Tract Defects
  mondo_id: MONDO:0100478
  category: Mendelian
  causal_genes: NFIA
  omim_id: not recorded
  synonyms: NFIA-related disorder; NFIA haploinsufficiency syndrome; chromosome 1p32-p31
    deletion syndrome; BRMUTD
provider_config:
  timeout: 1800
  max_retries: 3
  parameters:
    allowed_domains: []
    claude_executable: claude
    skip_permissions: false
    allowed_tools:
    - WebSearch
    - WebFetch
    add_dirs: []
    timeout: 1800
    min_report_chars: 200
    extra_args: []
run_metadata:
  models_used:
  - claude-haiku-5-5
  - claude-sonnet-5-5
  web_search_requests: 3
  num_turns: 7
  total_cost_usd: 0.8333385000000001
  session_id: 854e4ee6-1dd8-597a-ba53-1d9e860afb7a
  stop_reason: end_turn
  assistant_text_blocks: 1
citation_count: 6
reference_validation:
  total_references: 6
  verified: 6
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  relevance_assessed: 6
  on_topic: 4
  validator_version: 0.4.0
term_validation:
  total_terms: 1
  verified: 1
  not_found: 0
  obsolete: 0
  unverifiable: 0
  confabulation_rate: 0.0
  adapter: 'ols:'
  validator_version: 0.4.5
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Brain Malformations With Or Without Urinary Tract Defects
- **MONDO ID:** MONDO:0100478 (if available)
- **Causal gene(s):** NFIA
- **OMIM:** not recorded
- **Synonyms:** NFIA-related disorder; NFIA haploinsufficiency syndrome; chromosome 1p32-p31 deletion syndrome; BRMUTD
- **Category:** Mendelian

Many disease names are serial numbers ("... autosomal dominant 64", "... 26") that
do not say which gene the disease is about, and a similarly named disease with a
different gene is easy to research by mistake. Research the disease with the MONDO
ID and causal gene given above, and name its causal gene in your first paragraph.
If the name seems to point to a different gene or OMIM entry, follow the
identifiers above.

## Research Objectives

Please provide a comprehensive research report on **Brain Malformations With Or Without Urinary Tract Defects** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

# Brain Malformations With Or Without Urinary Tract Defects (BRMUTD): research report (NFIA)

**Scope and method.** This is a limited-depth pass: three searches and one successful fetch, run on 2026-10-24. The causal gene is **NFIA** (nuclear factor I A, 1p31.3), and the entity is the NFIA haploinsufficiency syndrome (MONDO:0100478 as supplied).

- OMIM returned 403, so I did not read the OMIM entry. I did not independently check the OMIM number, the MONDO ID, the HGNC ID or any HPO/GO/CL/UBERON/NCIT identifier. All ontology identifiers below are omitted on purpose, because I did not look any of them up. Every one needs a lookup before it goes into the KB.
- Statements are tagged by source class: [primary] = primary literature seen in a search result; [snippet] = search-engine summary of a source I did not read in full; [inference] = my reasoning, not sourced.
- Search-tool summaries are leads, not verified quotes. No exact-quote snippets could be extracted, so none are given. Each needs `just fetch-reference` and a verbatim snippet before curation.

## 1. Disease information

- NFIA haploinsufficiency (loss of one functional copy of NFIA) causes a CNS malformation syndrome with variable urinary tract defects. [primary: Lu et al. 2007, PLoS Genet, [PMC1877820](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1877820/), PMID 17530927. The PMID comes from the neuinfo result URL, not from the article itself.]
- In that report, 5 individuals had 1p31 rearrangements (balanced translocations or microdeletions). They shared thin, hypoplastic or absent corpus callosum and hydrocephalus or ventriculomegaly. Chiari I malformation, tethered cord and vesicoureteral reflux (VUR) were seen in subsets. [snippet of PMC1877820]
- The authors state that other genes were also disrupted in these 5 individuals and may contribute. NFIA haploinsufficiency was the only common defect. [snippet]
- Synonyms (from your template): NFIA-related disorder; NFIA haploinsufficiency syndrome; 1p32-p31 deletion syndrome; BRMUTD. I did not confirm these against OMIM, Orphanet or MONDO.
- **Lump/split call.** The entry mixes three allele classes: whole-gene or contiguous 1p31 deletions, translocation breakpoints, and intragenic loss-of-function or missense alleles. Contiguous deletions involve other genes, so they are not strictly NFIA-only. I would keep one entry and record the allele class and any contiguous-gene contribution as a note.
- The disease is a germline Mendelian disorder. There is no somatic tumor-predisposition aspect to separate. Whether NFIA has a somatic cancer role is outside this report and I did not check it.

## 2. Etiology

- **Cause.** Heterozygous loss of NFIA function: deletions, translocations, truncating variants, intragenic deletions, and some missense variants. [primary/snippet: PMC1877820; PMC8251549]
- **Missense.** The K125E (Lys125Glu) substitution is a recurrent allele reported in two unrelated patients, both with corpus callosum anomalies and macrocephaly. It was shown to be loss of function in these assays: Drosophila misexpression, zebrafish commissural axon rescue, and HES1 promoter regulation in cultured cells. [primary/snippet: [PMC8251549](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251549/), PubMed link 33973697 in the result list, PMID not confirmed against the article]
- A p.Arg115Gln missense (c.344G>A) was reported in a patient with a thin corpus callosum. [snippet: [Frontiers Pediatrics 2023](https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2023.1292654/full)]
- **Environmental, protective and gene-environment factors.** I found no evidence for any, and I did not search specifically. This is an acknowledged gap.
- **Modifiers.** None identified. Incomplete penetrance of urinary tract defects is documented (see section 3).

## 3. Phenotypes

All HPO term suggestions are names only. IDs still need lookup.

| Phenotype | Frequency and source |
|---|---|
| Corpus callosum hypoplasia/agenesis/thin | All 5 in Lu 2007 [snippet]; "defects in all" of 9 cases in a later literature review [snippet, PMC9777632] |
| Hydrocephalus / ventriculomegaly | All 5 in Lu 2007 [snippet]; present in all 9 early cases [snippet] |
| Chiari I malformation | Subset; 3 of 9 early cases [snippet] |
| Tethered spinal cord | Subset; 4 of 9 early cases [snippet] |
| Urinary tract defects (VUR, hydronephrosis, ureteral junction anomalies) | 3 of 5 in Lu 2007; 6 of 9 early cases [snippet]; absent in all 3 patients of one more recent series [snippet] |
| Macrocephaly | Common in later series [snippet: 2017 four-patient series, PubAnnotation PMID 28941020; Frontiers 2023] |
| Developmental delay / intellectual disability, hypotonia, seizures | Reported as common [snippet: GeneReviews NBK542336, which lists macrocephaly, seizures, hypotonia, developmental delay and recurrent UTIs] |
| Dysmorphic features | Listed among common findings in the 2017 series [snippet] |

- **Onset.** Congenital for the structural brain and urinary features, since they are malformations. Neurodevelopmental delay presents in infancy or childhood. [inference from malformation timing; onset ages were not sourced]
- **Progression.** Hydrocephalus and tethered cord can cause secondary progression. I found no natural-history data.
- **Quality of life.** No data found.
- **Denominators.** The numbers above are small, ascertainment-biased case series. A review of 24 patients with NFIA haploinsufficiency as the sole anomaly exists [snippet]. I did not retrieve its frequency table, so it is the best next source for HPO frequencies.

## 4. Genetic and molecular information

- **Gene.** NFIA at 1p31.3, a CCAAT-box-binding NFI-family transcription factor. The K125E and R115Q variants fall in the N-terminal DNA-binding/dimerization region. [snippet: PMC8251549 says DNA-binding-domain mutations likely affect function; the domain boundary is from my background knowledge]
- **Variant classes.** Contiguous 1p32-p31 deletions, translocations, intragenic deletions, truncating variants, and missense LoF (K125E, R115Q). [snippet: PMC9777632 review, GeneReviews]
- **Mechanism.** Loss of function through haploinsufficiency. [primary: PMC1877820; PMC8251549]
- **gnomAD, ClinVar, ClinGen validity, HGMD and DECIPHER.** Not queried. A ClinGen gene-disease validity record would have to be located and cited as CGGV. I have not verified that one exists.
- **Epigenetic findings, modifier genes.** None found.

## 5. Environmental information

None identified. I did not search CTD or the toxicology literature, and no infectious agent is involved.

## 6. Mechanism / pathophysiology

1. A heterozygous germline NFIA loss-of-function allele (deletion, truncation, translocation, or missense LoF) leaves roughly half the normal NFIA dosage. [primary: PMC1877820; PMC8251549]
2. Reduced NFIA transcriptional regulation impairs development of the midline commissures. This is supported by the zebrafish commissural axon rescue failure with K125E [snippet, PMC8251549] and by the Nfi-family knockout phenotype of dysgenesis of the corpus callosum, enlarged ventricles and megalencephaly [snippet, PMC8251549 background].
3. Failed or thin callosal formation leads to the callosal hypoplasia/agenesis seen in patients. The glial intermediate step is not supported in the sources I read. Nfia's role in glial and midline-glia specification is background knowledge and should be sourced before it is curated. [inference]
4. Ventricular enlargement and hydrocephalus follow. The mechanism is unverified here, and it may involve CSF dynamics or ependymal and glial defects. [inference]
5. In the urinary tract, Nfia dosage affects ureteral and renal development. Nfia+/- and Nfia-/- mice show abnormal ureteropelvic and ureterovesical junctions and bifid or megaureter. That leads to VUR and hydronephrosis, with variable penetrance. [primary/snippet: PMC1877820]
6. Chiari I and tethered cord are associated findings. A causal link to NFIA is unestablished. [inference]

- **Cell types and processes.** I would suggest radial glia/astrocyte-lineage progenitors, callosal midline glia, and ureteric/ureteral mesenchyme. These are [inference] and need CL and GO lookups.
- **Omics, single-cell, CRISPR screens.** None sourced.

## 7. Anatomical structures affected

- **Brain:** corpus callosum, lateral ventricles, posterior fossa (Chiari I). **Spine:** tethered cord. **Urinary tract:** ureteropelvic and ureterovesical junctions, ureter, kidney. All of these are sourced from section 3 snippets. UBERON IDs are not looked up.
- No lateralization data were found.

## 8. Temporal development

- Malformations are prenatal, so the onset is congenital.
- The course is lifelong. Complications follow from hydrocephalus, tethered cord and VUR (recurrent UTIs are listed in GeneReviews [snippet]).
- No remission or staging data were found.

## 9. Inheritance and population

- **Inheritance.** Autosomal dominant, haploinsufficiency. Whether variants usually arise de novo was not sourced. [inference: most reported cases are de novo, which I did not verify]
- **Penetrance and expressivity.** Variable. Urinary defects are in about half or more of cases in some series and absent in others. [snippet]
- **Prevalence.** Not found. I did not check Orphanet. Population, founder, consanguinity, sex-ratio and carrier-frequency data were not found, and none are expected for a de novo disorder.

## 10. Diagnostics

- **Imaging.** Brain MRI for callosal anomaly, ventriculomegaly and Chiari. Spinal MRI for tethered cord. Renal and bladder ultrasound, and voiding cystourethrogram for VUR. [inference from the phenotype list]
- **Genetic testing.** GeneReviews gives diagnostic routes: a heterozygous intragenic NFIA pathogenic variant, a 1p31.3 deletion including NFIA, or a rearrangement with a 1p31.3 breakpoint disrupting NFIA. [snippet: NBK542336]
- **Strategy.** Chromosomal microarray catches deletions and exome/genome or a gene panel catches intragenic variants. This follows from the GeneReviews criteria and is [inference].
- **Differential diagnosis.** Other callosal-dysgenesis and macrocephaly syndromes, including NFIB- and NFIX-related disorders. [inference]

## 11. Outcome and prognosis

No survival or quality-of-life data were found. Prognosis follows from the severity of hydrocephalus and neurodevelopmental delay, with the renal outcome depending on VUR. [inference]

## 12. Treatment

No disease-specific treatment was found. No clinical trials were searched, so I give no NCT IDs.

| Problem | Standard care | Source |
|---|---|---|
| Hydrocephalus | Neurosurgical CSF diversion if progressive | [inference] |
| Tethered cord | Neurosurgical release | [inference] |
| VUR | Urology surveillance and infection prophylaxis or surgery as needed | [inference] |
| Seizures | Antiseizure medication | [inference] |
| Developmental delay | Developmental therapies | [inference] |

NCIT treatment terms are not looked up.

## 13. Prevention

- Genetic counseling, with recurrence risk depending on de novo status versus parental carriage or mosaicism. Parental testing is needed. [inference]
- Prenatal or preimplantation testing is possible once the familial allele is known. [inference]
- Surveillance for urinary tract disease in a newly diagnosed child is reasonable given the frequency of VUR. Guideline support for this was not located.

## 14. Other species

No OMIA entries were checked. I have no sourced information on naturally occurring disease in other species.

## 15. Model organisms

- **Mouse.** Nfia knockouts show hydrocephalus and absent corpus callosum, per Lu 2007's account of earlier work. Nfia+/- and Nfia-/- also show ureteral and renal anomalies (ureteropelvic and ureterovesical junctions, bifid and megaureter). [snippet, PMC1877820]
- Nfi-family knockouts (Nfia, Nfib, Nfix) share overlapping brain defects: megalencephaly, callosal dysgenesis and enlarged ventricles. [snippet, PMC8251549]
- **Zebrafish and Drosophila.** These were used for functional testing of K125E. [snippet, PMC8251549]
- **Limitations.** The mouse recapitulates the callosal and urinary phenotypes. Human cases vary in urinary involvement, and the mouse Chiari/tethered-cord concordance is unsourced.
- **Resources.** MGI, IMPC and ZFIN were not queried.

## Gaps to close before curation

1. Read and quote the primary papers: Lu 2007 (PMC1877820), the K125E paper (PMC8251549), the 2023 Frontiers case report, and the PMC9777632 review.
2. Retrieve GeneReviews NBK542336, which is the mandatory baseline for a Mendelian entry, and find the 24-patient review's frequency table.
3. Confirm the PMIDs for the K125E paper (33973697) and the 2017 four-patient series (28941020). Both appear only in result URLs.
4. Look up every ontology ID, and check ClinGen validity and Orphanet.
5. Source the glial and midline-glia mechanism, which is currently inference.

## Sources

- [Lu et al. 2007, PLoS Genet, PMC1877820](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1877820/)
- [K125E loss-of-function paper, PMC8251549](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251549/)
- [Frontiers in Pediatrics 2023, NFIA case report](https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2023.1292654/full)
- [Phenotypic Spectrum of NFIA Haploinsufficiency, PMC9777632](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777632/)
- [GeneReviews NBK542336](https://www.ncbi.nlm.nih.gov/books/NBK542336/)
- [PubAnnotation record for PMID 28941020](https://pubannotation.org/docs/sourcedb/PubMed/sourceid/28941020)

## Reference Validation

Checked with `linkml-reference-validator` 0.4.0.

| Outcome | Count |
| --- | --- |
| References checked | 6 |
| Resolved | 6 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 6 |
| On topic | 4 |
| Off topic | 0 |

All extracted references resolved successfully.

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 1 |
| Resolved | 1 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 0 |
| Unverifiable | 0 |

Every term resolved, and every label the report gave matched.